Interchangeable Biosimilar

FDA, biosimilar

FDA plans to speed approvals of biosimilars

The Food and Drug Administration on Wednesday unveiled steps to streamline the way it approves lower-cost versions of biologic drugs, in a bid to curb health costs. Why it matters: After years of lagging uptake,

· 13h

FDA to Speed Biosimilar Approvals in Push to Cut Drug Costs (1)

· 6h · on MSN

FDA to streamline approvals of generic biologic drugs

· 15h

US FDA to streamline biosimilar approvals, FT reports

The U.S. Food and Drug Administration is preparing to accelerate approvals for biosimilars, or generic versions of complex biological drugs, the Financial Times reported on Wednesday.

IJR · 7h

FDA Encourages Cheaper Generics Of Pricey Medications

· 9h

Federal health officials push effort to spur cheaper biotech drugs

FDA announces plan to slash ‘sky-high’ drug costs and save Americans money

The FDA said it proposed significant changes to simplify biosimilarity studies and reduce what it described as unnecessary clinical testing of the lower-cost “generic” alternatives to

7hon MSN

FDA to streamline approvals for generic biological drugs in latest move targeting health costs

The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate approvals for cheaper alternatives for medications used to treat a wide range of illnesses,

Fierce Pharma

Amid Trump admin's drug pricing push, FDA aims to give biosimilars a boost

In new draft guidance, the FDA has taken steps to eliminate the clinical testing of biosimilars and to categorize all approved biosimilars as “interchangeable."

Trump Administration Eases Approval Process for Biosimilar Drugs

The Trump administration is proposing changes to Food and Drug Administration guidelines that would make it less expensive for drugmakers to develop biosimilar medicines, the copycat versions of off-patent biologic drugs.

Healio

Interchangeable biosimilars may cut costs or cause ‘cognitive dissonance’

The age of biosimilars has come for gastroenterology. This includes interchangeable products, three of which are now on the market. How this will impact patient care in the near and distant future is the subject of much speculation. While an increasing ...

CNBCTV18

USFDA accelerates biosimilar approvals process in the US — Four stocks that could benefit

So far, the USFDA has approved 76 biosimilars but the market share of these remains below 20% with only 10% of the biologics losing patent protection having a biosimilar in development.